Osservatorio Malattie Rare

What Osservatorio Malattie Rare does

Osservatorio Malattie Rare (OMaR), founded in 2010 and registered as a journalistic publication with the Rome Tribunal in 2011, is Italy's first registered national news agency exclusively dedicated to rare diseases and rare tumors. It operates a free-access digital editorial portal (www.osservatoriomalattierare.it) covering 100+ rare conditions across 11 thematic categories, complemented by six specialized observatories: Osservatorio Farmaci Orfani (OSSFOR), Osservatorio Screening Neonatale, Osservatorio Terapie Avanzate, Premio OMaR (journalistic award), Rare Sibling, and Alleanza Malattie Rare. Underlying technology is a multi-thematic portal architecture combining disease-specific sub-portals, news categories, and patient-facing service modules (Help Line 'L'esperto risponde', Sportello Legale OMaR), with content curated under a voluntary Scientific Committee of physicians, university professors, and researchers.

The platform serves patients with rare diseases and their families, healthcare professionals (physicians, researchers, pharmacists), journalists, and patient associations/advocacy groups, providing editorial coverage of research, clinical trials, orphan drugs, newborn screening, advanced therapies, healthcare policy, patient rights, and social services. Distribution is multi-channel: website, email newsletter, X, TikTok (@omarmalattierare), WhatsApp Channel, Threads, YouTube, and partner patient associations. Content is freely available to all users without registration or paywall.

The business model is a non-conditional sponsorship plus advertising model. Revenue comes from explicitly disclosed 'Partner' or 'Con il contributo di' sponsorships from pharmaceutical companies (Alexion, Alnylam, Chiesi Global Rare Diseases, Gilead, Pfizer), associations, and scientific societies, alongside clearly labeled on-site advertising. Sponsorships do not influence editorial independence. OMaR is published by Rarelab, operates as a registered Prodotto Editoriale under Italian Law 62/2001, and is led by Editor-in-Chief Ilaria Ciancaleoni Bartoli with a ~26-person team based in Rome.

Name

Osservatorio Malattie Rare

Legal name

Osservatorio Malattie Rare

Website

https://osservatoriomalattierare.it

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Osservatorio Malattie Rare is Italy's first registered national news agency dedicated to rare diseases and rare tumors, operating a free-access editorial portal covering 100+ conditions across six specialized observatories, funded by disclosed pharmaceutical sponsorships and advertising, and serving patients, families, clinicians, and journalists.

Ownership category

akta.pro rank

Headquarters

HQ city

Roma, Lazio

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Pharmaceutical company sponsorships: Non-conditional sponsorships from pharmaceutical companies, associations, and scientific societies interested in raising awareness on rare disease topics. These are explicitly disclosed on the website as 'Partner' or 'Con il contributo di' (With the contribution of) and do not influence editorial independence.
2. Advertising revenue: Proceeds from advertising appearing on the site's pages and other related advertising activities. All advertising is clearly labeled to distinguish it from editorial content.

Distribution channels4 records

Marketing channels10 records

Core offering

Osservatorio Malattie Rare is a registered national news agency and free-access digital editorial portal that publishes Italian-language news, analysis, and educational content on rare diseases, rare tumors, orphan drugs, newborn screening, clinical trials, and rare disease patient rights. Its core offering is the editorial website (www.osservatoriomalattierare.it) and its specialized sub-portals (Osservatorio Farmaci Orfani, Osservatorio Screening Neonatale, Osservatorio Terapie Avanzate), complemented by an expert Q&A helpline, a legal assistance service, downloadable guides, and the Premio OMaR journalism award. Content is produced independently with a voluntary Scientific Committee of physicians and researchers.

Product overview

Osservatorio Malattie Rare operates as a specialized national news agency dedicated to rare diseases and rare tumors. The core offering is the editorial website (www.osservatoriomalattierare.it) which serves as both a press agency for media and a public information portal. The platform is complemented by specialized service offerings including the Help Line "L'esperto risponde" for expert consultations and Sportello Legale OMAR for legal assistance. Additionally, the organization manages several distinct observatory projects (Osservatorio Farmaci Orfani, Osservatorio Screening Neonatale, Osservatorio Terapie Avanzate), a journalism award (Premio OMAR), the Rare Sibling support project, and publishes guides and educational materials for patients and families. The Alleanza Malattie Rare serves as an umbrella alliance for rare disease associations.

Differentiator

Problem solved

Functional benefit

Brands

• Osservatorio Farmaci Orfani (OSSFOR): Observatory dedicated to orphan drugs
• Osservatorio Screening Neonatale
• Osservatorio Terapie Avanzate
• Premio OMaR
• Rare Sibling
• Sportello Legale OMaR

Products and services

• Osservatorio Malattie Rare Website Free-access editorial news portal covering rare diseases, rare tumors, orphan drugs, clinical trials, healthcare policy, and patient rights in Italy. Functions as both a specialized press agency for media and a public information platform for patients and families.
• Help Line "L'esperto risponde" Expert Q&A service connecting rare disease patients and families with physicians and specialists for guidance on rare disease conditions.
• Sportello Legale OMaR Legal assistance service providing consultancy for rare disease patients on their rights, exemptions, civil disability benefits, and social support entitlements.
• Osservatorio Farmaci Orfani (OSSFOR) Dedicated observatory sub-portal monitoring orphan drugs, clinical trials, and pharmaceutical policies for rare diseases.
• Osservatorio Screening Neonatale Observatory sub-portal dedicated to neonatal screening programs and policies for early detection of rare diseases in newborns.
• Osservatorio Terapie Avanzate Observatory sub-portal focused on advanced biotechnologies including gene therapies, cell therapies, and innovative treatments for rare diseases.
• Premio OMaR Annual journalism award recognizing excellence in rare disease reporting; operated at www.premiomalattierare.it with over 40 prizes awarded since 2012.
• Rare Sibling Support project and content platform dedicated to siblings of rare disease patients, addressing their unique needs and challenges.
• Educational Guides and Publications (Le nostre pubblicazioni) Collection of free downloadable guides including 'Tutti i diritti dei talassemici', 'Guida alle esenzioni per le malattie rare', 'Speciale Testo Unico Malattie Rare', and 'La PGT in Italia' on preimplantation genetic testing.
• Guida ai Centri Italiani Directory services providing guides to Italian healthcare centers specializing in specific rare diseases including IPF, generalized pustular psoriasis, and hypophosphatemic rickets.

Quantifiable outcome

• Premio OMaR has assigned over 40 awards since 2012 recognizing excellence in rare disease journalism.

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Nine partnerships are on record, tiered core and minor.

• OrphanetcoreStrategic or Co-development PartnerOrphanet is a scientific partner of Osservatorio Malattie Rare. Orphanet is the reference portal for rare diseases and orphan drugs, providing authoritative disease information that is referenced and integrated into OMaR's content.
• TelethoncoreStrategic or Co-development PartnerTelethon is a scientific partner of Osservatorio Malattie Rare. Telethon is a major Italian foundation funding research on genetic diseases.
• EupaticoreStrategic or Co-development PartnerEupati (European Patients' Academy on Therapeutic Innovation) is a scientific partner, providing patient-focused training and education resources on biomedical research and drug development.
• Ospedale Pediatrico Bambino GesùcoreStrategic or Co-development PartnerOspedale Pediatrico Bambino Gesù is a scientific partner and Italy's leading pediatric research hospital, collaborating on rare disease content and clinical case reporting.
• Società Italiana di Endocrinologia (SIE)minorStrategic or Co-development PartnerScientific partner organization contributing expertise in endocrinology to rare disease coverage.
• Società Italiana di Genetica Umana (SIGU)minorStrategic or Co-development PartnerScientific partner organization contributing expertise in human genetics to rare disease coverage.
• Alleanza Malattie RarecoreStrategic or Co-development PartnerAlleanza Malattie Rare is a coalition of patient associations united under OMaR's coordination. It serves as a platform for collective advocacy, information sharing, and policy engagement on rare disease issues at national level.
• Centro DemetraminorStrategic or Co-development PartnerCentro Demetra collaborated with Osservatorio Malattie Rare to produce 'La PGT in Italia. Domande e risposte sulla diagnosi preimpianto per le coppie portatrici o affette da malattie rare e genetiche', an educational guide on preimplantation genetic testing for couples with rare and genetic diseases.
• RarelabcoreOthersRarelab is the publisher of Osservatorio Malattie Rare. Rarelab is identified as the publisher (Editore) of the publication.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Regional players

• National Organization for Rare Disorders (NORD): US-based rare disease patient advocacy organization providing disease information, policy advocacy, and patient support. Comparable to OMaR in mission and content categories, but serves the US market rather than Italy—making it a regional rather than direct peer.

Direct peers

• Global Genes: US-based rare disease advocacy organization producing educational content, toolkits, and awareness campaigns. Shares OMaR's model of serving patients, families, and clinicians through curated rare disease information and community engagement.
• EveryLife Foundation for Rare Diseases: US rare disease advocacy organization focused on policy and patient access. Comparable to OMaR in mission around legislative advocacy and patient empowerment, though geographically focused on the US.
• EURORDIS - Rare Diseases Europe: European non-profit alliance of rare disease patient organizations. EURORDIS operates as a pan-European peer to OMaR, sharing the mission of rare disease advocacy, policy engagement, and patient empowerment through information dissemination and coalition-building.
• Orphanet: European reference portal for rare diseases and orphan drugs, providing authoritative disease-level information. Orphanet is both a listed scientific partner of OMaR and a direct peer in delivering curated rare disease information to clinicians, patients, and researchers.
• Rare Diseases International: Global alliance of rare disease patient organizations. Operates at international level but mirrors OMaR's coalition-driven model through Alleanza Malattie Rare, advocating for rare disease policy and awareness worldwide.

Broad incumbents

• FiercePharma: Major pharmaceutical industry news publication covering drug commercialization, marketing, and policy. A broader incumbent serving the same pharma marketing audience that sponsors OMaR, but covering the full pharma industry rather than specializing in rare diseases.

Emerging players

• Orphan Drug World News / Pink Sheet Rare Disease: Specialist pharma industry publications covering orphan drug development, regulation, and commercialization. Adjacent peer serving pharma industry professionals with overlapping content on rare disease therapies and policy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/OssMalattieRare?lang=it
• TikToktiktok.com/@omarmalattierare?_t=8iyjwcbxiBF&_r=1
• LinkedInlinkedin.com/company/osservatoriomalattierare

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osservatorio Malattie Rare